ImmunityBio, Inc.
IBRX
$2.84
$0.176.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.66M | 14.19M | 7.12M | 1.25M | 302.00K |
| Total Other Revenue | 563.00K | 595.00K | 388.00K | 318.00K | 302.00K |
| Total Revenue | 31.22M | 14.75M | 7.33M | 1.31M | 302.00K |
| Cost of Revenue | 58.00K | -- | -- | -- | -- |
| Gross Profit | 31.16M | 14.75M | 7.33M | 1.31M | 302.00K |
| SG&A Expenses | 163.95M | 173.18M | 164.56M | 160.76M | 144.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 344.64M | 358.93M | 366.62M | 360.48M | 345.28M |
| Operating Income | -313.42M | -344.18M | -359.28M | -359.17M | -344.98M |
| Income Before Tax | -409.42M | -413.65M | -587.92M | -597.81M | -601.44M |
| Income Tax Expenses | -234.00K | -- | -40.00K | -40.00K | -40.00K |
| Earnings from Continuing Operations | -409.18 | -413.65 | -587.88 | -597.77 | -601.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 80.00K | 81.00K | 86.00K | 123.00K | 437.00K |
| Net Income | -409.10M | -413.56M | -587.79M | -597.65M | -600.96M |
| EBIT | -313.42M | -344.18M | -359.28M | -359.17M | -344.98M |
| EBITDA | -296.59M | -326.63M | -341.30M | -341.06M | -326.59M |
| EPS Basic | -0.55 | -0.60 | -0.87 | -0.94 | -1.05 |
| Normalized Basic EPS | -0.34 | -0.37 | -0.54 | -0.58 | -0.66 |
| EPS Diluted | -0.59 | -0.64 | -0.89 | -0.94 | -1.06 |
| Normalized Diluted EPS | -0.34 | -0.37 | -0.54 | -0.58 | -0.66 |
| Average Basic Shares Outstanding | 2.97B | 2.79B | 2.73B | 2.53B | 2.28B |
| Average Diluted Shares Outstanding | 2.97B | 2.79B | 2.73B | 2.53B | 2.28B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |